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ABSTRACT
MDD is a severe and debilitating disorder that is associated with a growing global economic
burden due to reduced workplace productivity along with increased healthcare resource
utilization. Furthermore, depression markedly enhances the risk for suicide, mortality that is
especially worrisome given that 30% of depressed individuals have an inadequate response to
current antidepressants. This inadequacy of antidepressants necessitates the discovery of a better
understanding of the pathobiology of MDD. Most current antidepressants work through
monoamine neurotransmitters, and their relative efficacy in depression led to the now dated
monoamine-deficiency hypothesis. The limited usefulness of antidepressants has led to a
reinvigorated search for other pathologies in depression that might yield clues for the
development of better drug treatments. In this regard, a strong association has been found
between oxidative stress and MDD. Our lab recently found increased DNA oxidation and
elevated poly(ADP)ribose polymerase (PARP1) gene expression in the brain from donors that
had MDD at the time of death. Besides DNA damage repair, PARP1 mediates several
downstream inflammatory effects that may contribute to pathology in MDD. In fact, our lab has
demonstrated that PARP-1 inhibition produces antidepressant-like effects in rodents, suggesting
that PARP-1 inhibitors hold promise as a novel antidepressant drug. While our lab had
previously demonstrated elevated PARP1 gene expression in the frontal cortex in MDD, whether
PARP1 protein levels were also increased in depression had not been verified. My thesis
research was performed to determine whether PARP1 protein expression was also elevated in the
brain in MDD. I studied primarily the hippocampus because it is part of the limbic (mediating
emotion) system of the brain and because previous research has shown numerous other
pathologies in the hippocampus. My study was carried out simultaneously as others in our lab
were measuring PARP1 protein levels in frontal cortex in MDD. This latter work was important
since the lab’s previous work had observed elevated PARP1 gene expression in the frontal
cortex, rather than in the hippocampus which was not previously studied. Hippocampal and
frontal cortical brain sections were cut from frozen blocks of both MDD and psychiatrically
normal control brain donors for these studies. PARP1 protein levels were estimated by assistedimaging software. The findings herein demonstrate that levels of PARP1 immunoreactivity are
significantly elevated in the frontal cortex of MDD donors as compared to control donors.
However, there was no change in PARP1 immunoreactivity in the hippocampus in MDD.
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Background:
Depression is an increasingly common disorder. Worldwide, the case count exceeds 120 million
people and, in an average population, the lifetime prevalence of the disease ranges from 10% to
15%1. In the U.S. alone, 17.3 million adults are expected to experience at least one major
depressive disorder within a year2. This prevalence does not come without due burden. The
annual economic cost associated with depression in the U.S. is estimated at $83 billion dollars
and individuals with increasingly severe depression have higher work productivity depletion
alongside higher, costly healthcare resource utilization3,4. More directly, depression and
contemplation of suicide are positively and significantly correlated with one another5. Thus, it is
anticipated that better treatments for depression could reduce morbidity as well as reduce overall
incidence of suicide. Better treatments are needed because an inadequate response to
antidepressants is linked with suicidal behavior6, and nearly 30% of individuals have an
inadequate response to current antidepressants7.
There have been a variety of theories introduced to explicate the pathophysiology of depression.
The most common hypotheses to address this issue are those related to genetic vulnerabilities,
the HPA axis, monoamine-deficiency, and neurotrophic dysfunction, amongst others8.
Significant progress has been made in elucidating the role of each of these areas as well as their
interactions with each other. However, the most widespread and common theory of depression is
rooted in the pharmacological actions of the most common drugs that are used to treat it. Almost
all current, established antidepressants regulate the monoamine neurotransmitter systems9.
The monoamine-deficiency hypothesis suggests that the root pathophysiology of depression is in
the reduced levels of monoamine neurotransmitters serotonin, norepinephrine, and/or dopamine
in the central nervous system10. Almost all compounds that have been shown to reduce
4

monoamine uptake, which results in increased levels of monoamines in the synaptic cleft, have
been observed as somewhat effective clinical antidepressants11. Prior to the 1980’s, the “first
generation” antidepressants which utilized this hypothesis were the monoamine-oxidase
inhibitors (MAOI’s) and tricyclic antidepressants (TCA’s). MAOI’s function by irreversibly
inhibiting monoamine oxidases, which metabolize the monoamine neurotransmitters, while
TCA’s inhibit the transport and reuptake of norepinephrine and serotonin at nerve terminals12,13.
However, both first-generation antidepressants, MAOI’s and TCA’s, have become significantly
less common in therapeutic use due to varying intolerable side effects14. To combat these effects,
in 1985, the first of the “second generation” antidepressants was introduced to the U.S. market.
These “second generation” drugs also followed from the monoamine-deficiency hypothesis and
are broadly categorized as selective serotonin reuptake inhibitors (SSRI’s) and selective
norepinephrine reuptake inhibitors (SNRI’s). The second generation antidepressants have
become more commonplace because of their better tolerability as compared to their first
generation predecessors, however, questions of broad efficacy remain15.
Although the second-generation antidepressants overcame the side-effect profile, the studies
measuring their efficacy have not been promising. In a study measuring the SSRI citalopram,
only 30% of patients showed full remission16. While yet another that utilized SSRI’s in
combination with other treatment modalities – this combination of treatments is often referred to
as “antidepressant treatment” (ADT) – showed ineffectiveness in 20-30% of patients17. This
treatment-resistant depression indicates incompleteness in the monoamine-deficiency hypothesis
as the pathophysiological basis of depression and underscores the need for further research of
depression pathobiology to identify new targets for the development of better drugs.
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Recent research has alluded to the role of the immune system as a promising link between stress
and depression18,19. One of these models has proposed that chronic stress activates the immune
system such that inflammation ensues, and the resulting chronic inflammation leads to
depressive symptomology19. More specifically, several studies have indicated elevated oxidative
stress and inflammation in patients exhibiting MDD20–33. Extrapolating from this, studies have
found oxidative damage to nucleic acids in MDD34–36. These discoveries led our lab to examine
and find that DNA oxidation is elevated in white matter oligodendrocytes in the frontal cortex
from MDD brain donors37. This damage is further associated with a reduced antioxidant enzyme
gene expression in white matter oligodendrocytes38. Collectively, these findings have shown that
oxidative stress and its role as a contributor to the development of MDD is promising.
In an MDD patient, reactive oxygen species (ROS) can alter several cellular molecules,
including DNA. When an ROS attacks DNA, this activates the cell’s base excision repair (BER)
system. The BER pathway activates two specialized enzymes that are involved in the repair of
oxidized nucleotides and/or deoxyribose moieties: poly(ADP-ribose) polymerase-1 (encoded by
PARP1) and 8-oxoguanine DNA glycosylase (encoded by OGG1). The gene expression of both
of these enzymes is induced by oxidative stress conditions39. OGG1 recognizes oxidized DNA
and recruits the enzyme AP endonuclease I to form a single strand break (SSB) at the site of
oxidation. PARP1 recognizes and binds the SSB using its DNA-binding domain and is
subsequently activated. An activated PARP-1 begins synthesis of poly(ADP-ribose) (PAR) on
itself (“PARylates” itself) and other local proteins. The formed PAR on PARP-1 at the site of the
SSB serves as a signal to recruit other DNA repair enzymes: x-ray repair cross-complementing
protein 1 (XRCC1), DNA polymerase-ß, and DNA ligase III. These recruited enzymes work

6

together to replace the excised base and conclude the base-excision repair process40–42. Par
glycosylase (PARG) cleaves PAR from PARP1, restoring PARP1 to its original state.
Given its role described above, it is understandable that PARP-1 is upregulated under increased
levels of oxidative damage to DNA and conditions of oxidative stress43,44, i.e. it is upregulated in
response to an increased need for DNA repair. Previous research from our lab demonstrated
elevated PARP-1 gene expression in frontal cortical white matter from MDD brain donor
patients38. These findings allude to a role of PARP-1 beyond base-excision repair. It is known
that PARP-1 is involved in key inflammatory processes. PARP1 associates with and activates
several transcription factors involved in inflammatory gene expression, most notably nuclear
factor kappa B (NF-κB)45. Additionally, free PAR chains that have been cleaved by PARG from
PARP1 and other proteins, serve as damage associated molecular patterns (DAMP) that are
recognized by macrophages and lead to further inflammation46. On top of its role in driving
inflammation, PARP1 activity leads to a depletion in cellular energy stores that results in cell
death47–51. These additional effects of PARP1 coupled with the aforementioned findings indicate
a potential role of PARP1 in MDD pathobiology.
Given this knowledge, it is possible that the downstream inflammatory effects of PARP1
upregulation mediate the disruption of emotional behaviors associated with MDD. An approach
to test this association would be to pharmacologically inhibit PARP1 and produce the anticipated
antidepressant effects in animal models of depression. Our lab tested this and, indeed, small
molecule inhibition of PARP1 was found to produce antidepressant-like effects in two rodent
models52. These findings indicate the promising role of PARP-1 inhibitors as possible
antidepressant treatments for MDD patients, nevertheless, more research is needed to increase
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confidence in PARP1’s potential role as a critical mediator of behavioral disruption in human
MDD patients.
The research herein had two goals. One goal was to determine whether elevated PARP1 gene
expression in MDD is associated with elevated PARP1 protein levels. This is an important issue
because elevated gene expression of a given enzyme is not always accompanied by elevated
enzyme levels and/or elevated levels of enzyme activity. Hence, we used an antibody against
human PARP1 to quantify PARP1 protein in MDD and normal control donors. A second goal
was to achieve a better understanding of whether PARP1 upregulation is restricted to frontal
cortical white matter. It is known that different areas of the brain have varying sensitivities to
oxidative damage53, with white matter oligodendrocytes being particularly susceptible. Studies
have also indicated the hippocampus as an area of the brain containing neurons that are
particularly susceptible to oxidative damage54,55. A previous study demonstrated elevated DNA
oxidation in the hippocampus of depression-induced animals56. It is also noteworthy that the
hippocampus is part of the emotional (limbic) brain, and a large number of studies have
demonstrated other pathologies of the hippocampus in MDD. Hence, it is evident that the
hippocampus is a promising area for observing changes in PARP1 levels in MDD patients. An
accompanying study in the lab that paralleled my thesis project was the measurement of PARP1
levels in the frontal cortex, where PARP1 gene expression was previously found to be elevated.
This parallel study was critical to the interpretation of my work since PARP1 protein levels had
yet to be confirmed in the same brain region in MDD that gene expression changes were
observed. The results of this study and the parallel study are reported here and provide clarity as
to where in the brain the PARP1 pathobiology occurs and will contribute to further development
of PARP1 inhibitors as possible antidepressant drugs.
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Methods
Human Brain Tissue Sectioning and Storage
Frozen human hippocampal and frontal cortical (Brodmann area 10) brain sections were cut 20
µm thick in a cryostat at -17 ℃. These sections were transferred onto Superfrost Plus slides.
These slides, now with the sections, were dehydrated in a vacuum desiccator overnight at 4 ℃.
The next day, the slides were transferred from the desiccator to a -80 ℃ freezer for storage.
PARP1 Immunohistochemistry
The slides were fixed in cold acetone at -20 ℃ for 20 minutes. After fixing, they were washed 4
times (10 minutes each time) in phosphate-buffered saline (PBS) at room temperature (RT). The
slides were then blocked and permeabilized in PTB buffer (PBS, 3% Triton X-100, 1% BSA) at
RT for 1 hour. PARP-1 antibody (rabbit, 1:500 dilute in PTB) was used to incubate the slides at
4℃ overnight (*negative control is without PARP-1 antibody). The next day, the slides were
washed in PBS 3 times (10 minutes each time) at RT. The slides were then incubated with the
secondary antibody (donkey anti-rabbit Alexa Flour 594; dilute in PT; PBS, 3% Triton X-100) at
RT for 1 hour. Next, the slides were washed in PBS 3 times (10 minute each time) at RT. A
single drop of the mounting medium with DAP1 (fluorescent counterstain) was applied on each
section, the drops were mounted with coverslips of which to the edges were applied clear nail
polish to maintain placement. These were let to dry and later stored at 4 ℃. Slides were
immuno-stained in batches of which contained equal numbers tissue sections of psychiatrically
normal control and MDD donors.
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Imaging with EVOS
An EVOS fluorescent microscope was used to take immunofluorescent images of the slides. The
auto-imaging system of EVOS was utilized to scan the hippocampus or frontal cortex for future
analysis. There are two stitching patterns for each region identified. One is with DAP1
fluorescent signaling (blue color; labels nuclei of cells), and the other is with PARP1 fluorescent
immune activity signaling (red color). Negative control slides were used to set a parameter to
exclude non-specific PARP-1 fluorescent immune-activity signaling.
MCID-Core Image Analysis
Both stitching patterns of a region (DAP1 and PARP1) were loaded onto 2 separate channels on
MCID-Core image analysis software. Our lab decided on using the dentate gyrus (DG) region of
the hippocampus to set a density parameter within a range of 3-5%. This parameter was then
applied to find the PARP1 area fraction, i.e. the fraction of the analyzed area that was above
background, in different hippocampal regions (CA1, CA4, DG, etc.) or frontal cortex subregions
(layers 1-3, layers 4-6, white matter) within each experimental batch (containing MDD and
control sections). For each batch, this same protocol was used: identify the first subsection, set
the density parameter according to DG or cortical region of this subsection, apply parameters to
find PARP1 area fraction of the hippocampal or cortical regions within the all the subsections of
the batch. Each PARP1 area fraction was automatically stored by the MCID-Core software and
these data points were later transferred to Microsoft Excel for organization and analysis. The
analysis of images was done blind to whether hippocampal and cortical tissue sections came
from MDD or control donors.
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Statistical Analyses
Area fractions, as estimates of levels of PARP1 immunoreactivity, in brain regions from control
and MDD donors were subjected to outlier analysis using ROUT (GraphPad Prism v.8.4.2).
Corrected data were then analyzed using a one-way ANOVA. When the p value for the
ANOVA was < 0.05, Sidak’s multiple comparisons test was used to determine which brain areas
demonstrated statistically significant differences between control and MDD donors. Again, a
p<0.05 was considered statistically significant.
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Results

Hippocampus

Figure 1. PARP1 area fraction in several hippocampal regions of both MDD and psychiatrically
normal control groups gathered using the MCID-core imaging software

PARP1 area fraction collected in several hippocampal regions in both MDD and control groups
is shown in Figure 1. PARP-1 area fraction levels across the different hippocampal regions were
highly variable with the DGg region having the highest levels in both groups (MDD and control).
However, for each of the CA1, CA4, DGg, DGm, and Alv hippocampal regions there was no
significant difference between the PARP-1 area fractions of the MDD and control groups
(p<0.05).
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Figure 1. PARP1 area fraction in several BA10 frontal cortex regions of both MDD and normal
control groups gathered using the MCID-core imaging software

PARP1 area fraction collected in regions of the BA10 frontal cortex in both MDD and non-MDD
groups is shown in Figure 2. PARP1 area fraction varied across the BA10 frontal cortex regions
with white matter having the highest levels. The white matter was also the only region that
demonstrated significantly increased PARP1 area fraction in MDD donors as compared to
control donors (p<0.05).
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Discussion
In this study PARP1 protein levels were evaluated in the hippocampal and BA10 frontal cortex
regions of both MDD and psychiatrically normal brain donors. This study was intended to
elucidate whether the previously reported elevation of PARP1 gene expression in MDD is
associated with elevated levels of PARP1 protein and to also determine if PARP1 upregulation in
MDD is limited to the prefrontal cortex. The results demonstrated significantly elevated levels of
PARP1 protein in the white matter of the frontal cortex of MDD donors, with no such increase of
PARP1 protein levels in the hippocampus of MDD donors. The implications of these results are
wide-ranging and will contribute to further understanding of the pathophysiology of depression
as well as the potential development of PARP1 inhibitors as antidepressant drugs.
In previous studies, our lab tested the hypothesis that exposure to PARP1 inhibitors will lead to
antidepressant-like effects. In order to measure this, rats were exposed to several psychological
stressors, including combined social defeat and chronic unpredictable stress, which have both
been proven to be effective models for measuring antidepressant effects57. Concurrently, the
Porsolt swim test, which is commonly used to identify antidepressant drugs, was used57,58. To
test the pharmacological ability of PARP1 inhibitors in producing antidepressant effects, rats
were divided into four groups, including three treatment groups and one control. Treatment
groups were given 3-aminobenzamide (3-AB; PARP1 inhibitor), fluoxetine (SSRI), and normal
saline, and each treatment group was simultaneously exposed to psychological stressors. Control
groups were given saline but were not exposed to psychological stressors. Antidepressant-like
effects were measured using the sucrose preference and social interaction times test – an increase
in each would suggest an effective antidepressant. The PARP inhibitor 3-AB increased both
sucrose preference and social interaction times as compared to control rats, mediating effects
14

comparable to those produced by fluoxetine52. Moreover, 3-AB also demonstrated
antidepressant-like activity in the Porsolt swim test, facilitating reduced immobility time and
increased latency to mobility52. These results indicated that PARP1 inhibitors may produce
antidepressant effects in MDD patients. This finding, coupled with the demonstrated
upregulation of PARP-1 in BA10 frontal cortex white matter of both MDD and suicide
patients38, opened the door for the promising development of a truly novel antidepressant drug. A
part of this development is gaining a better understanding of what area(s), if any, of the brain
beyond the BA10 frontal cortex demonstrate PARP1 upregulation.
In one of our original studies, white matter oligodendrocytes from the frontal cortex (Brodmann
area 10, BA10) were used to measure DNA oxidation and PARP1 gene expression in human
MDD38. This is because white matter oligodendrocytes are particularly susceptible to oxidative
damage and there is relative ease in collecting them from human postmortem brain sections.
White matter oligodendrocytes were chosen from the frontal cortex because of previous studies
associating increased activation of BA10 with depressive behaviors59. Another area of the brain
that is especially sensitive to oxidative stress is the pyramidal neuron of the CA1
hippocampus54,55. The hippocampus is a part of the brain system responsible for memory
consolidation and emotional responses60. Several studies have indicated hippocampal volume
reductions, abnormal hippocampal gene expression, and reduced hippocampal neurogenesis in
MDD and suicide61–70. Thus, we postulated that this region would show elevated PARP1
expression similar to frontal cortical white matter. Contrary to expectations, PARP1 protein
expression was not significantly elevated in the hippocampus of MDD donors as compared to
control donors. This doesn’t necessarily suggest that there is no involvement of PARP1 in the
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hippocampus in MDD, since it may be regulated in this brain area differently than in the frontal
cortex.
The hippocampus is one of the regions of the brain with the highest PARP1 mRNA levels. In
contrast, frontal cortical white matter is a brain region with very low levels of PARP1 gene
expression. Following from this, it seems possible that PARP1 production by cells in the
hippocampus may be near maximum, and that cellular stress (eg. DNA oxidation) putatively
associated with MDD may not be accompanied by further increase in PARP1 expression. An
increase of PARP1 protein levels in the hippocampus was anticipated because of strong
associations of the hippocampus with MDD, and the noticeable upregulation of gene expression
of PARP1 in the BA10 frontal cortex of MDD patients38. However, the activity of the PARP1
enzyme, as with any enzyme, is regulated at several cellular levels including changes in gene
expression, translated protein levels, and in several post-translational modifications that can
modify enzyme activity. A lack of increase in enzyme protein levels does not necessarily mean
that there is no change in enzyme activity. A limitation of this study is that only translated
PARP1 protein levels were measured and compared in MDD and control brain donors. It is
possible that in MDD patients, PARP1 is post-translationally modified such that, even if the
protein expression levels remain comparable to controls, protein activity could be elevated. The
possibility that increased PARP1 activity occurs in MDD should be investigated before any
conclusions are made about the role of PARP1 in hippocampal pathology associated with MDD.
Our lab’s original study demonstrated significantly elevated PARP1 gene expression in white
matter from the BA10 frontal cortex of MDD donors38, and the present study found significantly
elevated PARP1 protein levels from the same area in MDD donors. This indicates that PARP1
gene expression is positively correlated with protein levels. While this is promising, further
16

studies, as with the hippocampus, need to demonstrate how PARP1 protein expression is
associated with protein activity in the BA10 frontal cortex. Collectively, these studies would
make significant contributions in elucidating the promising PARP1 pathobiology model.
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